Looking to the Future

PUBLISHER'S NOTE

As we continue this new year, there are still many uncertainties. At press time, the omicron variant was causing a record number of cases, adding to the stress of already taxed clinicians like yourself. In addition, this new wave continues to add to anxiety and disruptions in patients’ lives. Although we all wished we had turned the corner of the pandemic, the reality is we will continue to feel its effects for some time.

With that in mind, this month Psychiatric Times^TM shares valuable clinical pearls to support you and your patients. For instance, Teofilo Matos Santana, MD, and colleagues found the pandemic has led to a new variety of malingering. They draw from their clinical experience to shine a light on unique behavioral maladaptations to crises as well as the medical-ethical dilemmas that arise from such. Their clinical pearls are great reminders of the importance of listening to patients and really understanding their circumstances.

Meanwhile, the usual clinical challenges still arise, like finding the best treatment strategies for patients with schizophrenia. Often, there is a need to switch antipsychotics, and doing so can be complicated. To support you in this endeavor, John J. Miller, MD, shares 10 factors to consider when cross-titrating these medications in this month’s continuing education article. His thoughtful explanations provide a roadmap to successful outcomes.

Of course, you also will find many of the usual clinical articles, features, and commentaries that have you reading Psychiatric Times^TM from cover to cover. As we look to the future, our goal continues to be to support you, our readers, in all things psychiatry related. ❒

Mike Hennessy Jr

President and CEO, MJH Life Sciences^®